drugset

drugset / Trial / NCT05939947

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

NCT05939947 ↗

Phase 1 Completed 41 enrolled Alentis Therapeutics AG

RandomizedSequentialTriple-blindBasic science

Summary

The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.

Timeline

Start: 2023-04-01
Primary completion: 2024-10-30
Completion: 2024-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LIXUDEBART	Monoclonal antibody	—	Intravenous

Indications